Urinary Extracellular Vesicles Reveal Distinct Biological Effects of Voclosporin in the Treatment of Lupus Nephritis (KIDNEY WEEK 2023) - Oct 15, 2023 - Abstract #TH-PO550; Pres time: Nov 2, 2023; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Pennsylvania Convention Center; "Funding: Commercial Support - Aurinia PharmaceuticalsBackground: In the Phase 2 AURA-LV and Phase 3 AURORA 1 trials the novel calcineurin inhibitor voclosporin significantly increased complete renal response rates compared to placebo, both including mycophenolate mofetil and low-dose steroids. Using mass spectrometry of uEV we identified potential non-invasive biomarkers for treatment response to voclosporin in patients with LN. In addition, we were able to characterize the altered processes in the patients responding to voclosporin, which included complement and a specific change in neutrophil-associated proteins."
Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Martijn H. van Heugten1; Kuangyu Wei1; Hester van Willigenburg1; Fatih Demir2; Linda M. Rehaume3; John Viel3; Markus M. Rinschen2; Ewout J. Hoorn1
|